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Pulmonary extra-intestinal manifestations (EIM) of inﬂammatory bowel disease are well described with
a variable incidence. We present a case of Crohn's disease with pulmonary EIM including chronic
bronchitis with non-resolving bilateral cavitary pulmonary nodules and mediastinal lymphadenopathy
successfully treated with inﬂiximab. Additionally, we present a case summary from a literature review on
pulmonary EIM successfully treated with inﬂiximab. Current treatment recommendations include an
inhaled and/or systemic corticosteroid regimen which is largely based on case reports and expert
opinion. We offer inﬂiximab as an adjunctive therapy or alternative to corticosteroids for treatment of
inﬂammatory bowel disease related pulmonary EIM.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Inﬂammatory bowel disease (IBD), which includes Crohn's dis-
ease and ulcerative colitis, is a chronic inﬂammatory condition
primarily associated with the gastrointestinal tract. These diseases
have numerous extra-intestinal manifestations (EIM), such as
pyoderma gangrenosum, episcleritis, uveitis, polyarticular arthritis,
thromboembolic disease and a myriad of pulmonary abnormalities
[1]. Pulmonary EIM are considered rare manifestations of IBD
despite increasing evidence suggesting frequent pulmonary
involvement [2e4]. Numerous case series and review articles have
been published, describing a variety of pathologic and radiologic
presentations [2,3].
Despite increasing awareness and knowledge about IBD asso-
ciated pulmonary disease, little is known about its treatment.
Current treatment recommendations are empirical and based upon
expert opinion, with an emphasis on the use of inhaled or systemic
corticosteroids [3,5]. Because of the low incidence and highisease; EIM, extra-intestinal
esentation at Chest in Austin,
icine, Division of Pulmonary,
mple, TX 76508, USA.
fanner@sw.org (T.P. Pfanner),
Ltd. This is an open access article uvariability in presentation, randomized controlled trials to evaluate
treatment efﬁcacy have not been performed.
Inﬂiximab, a chimeric monoclonal antibody against tumor ne-
crosis factor (TNF) alpha, can be used for the treatment of moderate
and severe IBD. Additionally, inﬂiximab has also been shown to
improve some EIM refractory to conventional immunosuppressive
therapy. Only a few cases of IBD associated pulmonary EIM treated
with inﬂiximab are found in the literature [6e11]. We present a
case of Crohn's diseasewith pulmonary EIM treatedwith inﬂiximab
and a literature review.
2. Case report
A 33-year-old morbidly obese male, employed as a prison guard,
presented with a six week history of cough. The patient subse-
quently developed fever, nausea, occasional emesis, non-bloody
diarrhea and a 25-pound unintentional weight loss. A chest
radiograph revealed a patchy nodular shaped density in the left
lower lobe. The patient received two courses of antibiotics with
resolution of the fever but persistence of the inﬁltrate on serial
chest radiographs. Given the persistent inﬁltrate and abdominal
symptoms, pulmonary and gastroenterology referrals were
ordered.
Chest, abdominal and pelvic computed tomography were ob-
tained at the time of gastroenterology evaluation, revealing scat-
tered bilateral cavitary pulmonary nodules with parenchymal
airspace disease in the left lower lobe and mediastinal lymphade-
nopathy (Fig.1e left column). Additionally, mesenteric lymph nodender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Chest computed tomography before (left column) and after (right column) therapy.
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terminal ileumwas noted. Subsequent colonoscopy revealed colitis
of the ascending colonwith friable mucosa and skip lesions. Forcep
biopsies within the ascending colon demonstrated marked chronicactive colitis with crypt abscess formation and focal areas suspi-
cious for granuloma, consistent with Crohn's disease.
Following pulmonary evaluation, ﬂexible bronchoscopy
revealed negative bacterial, fungal, and acid-fast cultures and
Table 1
Literature review of inﬂiximab therapy for pulmonary extra-intestinal manifestations.
Age
(yrs)
Sex Duration
(yrs)*
Type Radiographic ﬁndings Pathology PSE MES 6-MP AZI INF
Alrashid [6] 66 F 3 Crohn's Pulmonary nodules BOOP, NCG X C
Gill [7] 20 F 9 Pulmonary nodules
Liver nodules
NCG X C
Krishnan [9] 13 F 4 Pleural and intraparenchymal inﬁltrates
without lymphadenopathy
NCG X XC C
14 F 3 Scattered granulomatous lesions without
lymphadenopathy
NCG X XC C
17 M 4 Bilateral basal inﬁltrates and effusions BOOP C X X C
Kirkcaldy [8] 41 F 2 Concentric soft-tissue thickening
Glottis to intrathoracic trachea
NCG X C
Silbermintz [11] 13 F 3 Multilobar consolidation
Pleural and intraparenchymal inﬁltrate
NCG X X C
Pedersen [10] 35 F 11 Pulmonary nodules, Parenchymal inﬁltrates,
Pleural effusions
NCG X X C
Case Report 33 M 0 Cavitary pulmonary nodules
Parenchymal airspace disease
Mediastinal lymphadenopathy
Bronchitis
Intra-alveolar
macrophages
XC XC C
PSE e Prednisone, MES e Mesalamine, 6-MP e 6-mercaptopurine, AZI e Azithioprine, INF e Inﬂiximab, NCG e Noncaseating Granulomas, BOOP e Bronchiolitis Obliterans
with Organizing Pneumonia, X e Incoming maintenance therapy,C e Discharge therapy, * e Duration from IBD to EIM presentation.
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bronchitis with intra-alveolar macrophages. No evidence of ma-
lignancy was found. Serologic evaluation including, fungal serol-
ogies, HIV antibody, anti-neutrophil cytoplasmic antibodies,
urinary and serum histoplasma antigen, cryptococcus antibody,
and galactomann aspergillus assay were all negative. T-spot and
Mantoux screening test were negative as well.
After diagnostic evaluation, treatment consisted of prednisone
and mesalamine, which improved his diarrhea although the lung
disease persisted. After consulting with gastroenterology, the pa-
tient was started on inﬂiximab and responded both clinically with
the resolution of his cough and radiographically with marked
decrease in the size of the cavitary lung lesions and mediastinal
lymphadenopathy (Fig.1e right column). The time period between
pre and post computed tomography evaluation as shown in Fig. 1
was approximately 6.5 months with an interval evaluation
revealing stability of ﬁndings prior to inﬂiximab administration.
The follow-up imaging was performed approximately 2 months
after treatment with inﬂiximab.3. Discussion
The prevalence of IBD is 396/100,000which is approximately 1.4
million Americans [12]. In general, extra-intestinal manifestations
of IBD have been reported in anywhere from 6 to 47% of cases [1].
When pulmonary EIM have been speciﬁcally studied the preva-
lence has been highly variable, depending on the diagnostic criteria
and clinical or subclinical nature. Most studies reveal pulmonary
manifestations in 30e60% of patients [2,3], while some studies
have revealed a much lower incidence (<1%) [4]. Despite some
studies having a low incidence, the general consensus would
advocate that pulmonary EIM are grossly under recognized. With
this in mind, studies have identiﬁed pulmonary EIM through
symptoms (44e50%), imaging (25e50%), pulmonary function test
(42%), bronchoalveolar lavage (50%), and through population
studies identifying an increase incidence of VTE and asthma [2].
Pulmonary function tests have not been found to be overly useful or
reliable in the setting of pulmonary EIM identiﬁcation. Multiple
reports have demonstrated a decreased diffusion capacity and
other reports have variably shown airﬂow obstruction, small
airway dysfunction, increased functional residual capacity, hyper-
inﬂation and bronchial reactivity to methacholine challenge [2].The most common interstitial and airway pulmonary EIM have
been found to be bronchiolitis obliterans organizing pneumonia
and bronchiectasis respectively [3,13].
Literature review reveals primarily expert opinion regarding
therapy. The diagnosis and directed therapy for pulmonary IBD EIM
is reserved for patients with symptoms and abnormal imaging that
is unaccounted for after an extensive workup including infectious,
autoimmune and pathologic evaluation. Spontaneous resolution
has been described and delay in diagnostic evaluation could lead to
a failed diagnosis. Corticosteroids have been the mainstay of
treatment used in about 2/3 of cases; however, up to 1/3 of patients
fail treatment either because they do not respond or cannot be
tapered off corticosteroids [2,3]. It is important to note that corti-
costeroid failure is less common in upper airway involvement,
interstitial lung disease, cavitary pulmonary nodules and serositis
[3,5]. A graded mixture of inhaled and oral corticosteroids at high
doses has been recommended based on the nature of pulmonary
involvement [3]. With such a rare problem, RCT are unlikely and
case reports with expert opinion often lags behind new treatment
modalities.
Inﬂiximab therapy has been shown to be efﬁcacious in other
EIM's that have generally failed conventional immunosuppressive
therapy. They have been speciﬁcally shown to be effective in IBD
EIM such as spondylarthropathies, refractory erythroderma nodo-
sum, pyoderma gangrenosum, sweets syndrome and uveitis [14].
Interestingly, patients with pulmonary EIM have been concurrently
seen to have other EIMs such as pyoderma gangrenosum and
spondylarthropathies [15]. When the use of inﬂiximab for pulmo-
nary EIM was reviewed, only eight cases (Table 1) were discovered
[6e11]. Most were case reports or brief case series in patients with
Crohn's disease. Two cases, including our own, had pulmonary EIM
diagnosed before or at the time that the IBD was diagnosed. All
patients received extensive evaluation including tissue sampling to
assist in diagnosis. In these cases, inﬂiximab was the only anti-TNF
that was used as either adjunctive or monotherapy. All cases
resulted in clinical and radiographic resolution of the pulmonary
IBD EIM.4. Conclusion
We present a case of Crohn's disease with pulmonary EIM suc-
cessfully treated with inﬂiximab. With review of the literature
A.J. Hayek et al. / Respiratory Medicine Case Reports 15 (2015) 85e8888demonstrating possible efﬁcacy, we would advocate inﬂiximab as
an adjunctive or alternative therapy to corticosteroids in pulmo-
nary EIM of IBD until appropriate randomized controlled trials can
be performed. If inﬂiximab is considered as an alternative therapy,
diligence must be used to exclude infectious etiologies, particularly
mycobacterial and fungal disease given probable previous history
of immunosuppressant use and the risks associated with inﬂiximab
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